Myosin Therapeutics Inc
Myosin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for cancer and neurological disorders. The company is advancing its lead compound, MT-125, designed to treat glioblastoma by targeting a molecular nanomotor to inhibit tumor growth and invasion. The FDA has granted orphan drug designation to MT-125 for malignant gliomas, highlighting its potential to significantly improve patient outcomes.
Leadership & Board
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 1,005
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $8M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $5M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Employee Trend
Myosin Therapeutics Inc had 9 employees as of October 19, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Myosin Therapeutics Inc had 1,005 followers as of October 19, 2026. The number of followers increased by 2 (0.20%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 19, 2025 | Investment | $4.50M | ― |
| Mar 03, 2025 | Seed Round | $3.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| UK Innovation & Science Seed Fund | Investment |
Similar Companies
A snapshot of private companies similar to Myosin Therapeutics Inc, helping you discover and navigate related company profiles.
Related News and Analysis
